GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B7763 Prosaptide TX14(A)Summary: GPR37L1 and GPR37 agonist -
B5023 Pronethalol hydrochlorideSummary: β-adrenergic antagonist -
B5033 NociceptinSummary: Endogenous ligand for the NOP opioid receptor -
B5049 [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2Summary: Potent agonist of the nociceptin (ORL1) receptor -
B5052 Nocistatin (bovine)Summary: endogenous peptide used to block nociceptin-induced allodynia and hyperalgesia -
B5053 NocIISummary: Orphan neuropeptide,stimulates locomotion in mice -
B5057 BombesinSummary: Neuropeptide with many biological effects -
B5058 CCK Octapeptide, non-sulfatedSummary: Non-sulfated form of the C-terminal octapeptide of CCK -
B5060 Pancreatic Polypeptide (human)Summary: Endogenous high affinity agonist for human NPY Y4 receptor -
B5061 CGRP (rat) TFASummary: Endogenous neuropeptide, potent vasodilator

